- Home
- ONFO vs APTO Comparison
ONFO vs APTO Comparison
Compare ONFO & APTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONFO
- APTO
- Stock Information
- Founded
- ONFO 2018
- APTO 1986
- Country
- ONFO United States
- APTO Canada
- Employees
- ONFO N/A
- APTO N/A
- Industry
- ONFO Computer Software: Programming Data Processing
- APTO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ONFO Technology
- APTO Health Care
- Exchange
- ONFO Nasdaq
- APTO Nasdaq
- Market Cap
- ONFO 6.2M
- APTO 6.8M
- IPO Year
- ONFO 2022
- APTO N/A
- Fundamental
- Price
- ONFO $0.93
- APTO $1.71
- Analyst Decision
- ONFO
- APTO Strong Buy
- Analyst Count
- ONFO 0
- APTO 3
- Target Price
- ONFO N/A
- APTO $112.00
- AVG Volume (30 Days)
- ONFO 31.1K
- APTO 58.8K
- Earning Date
- ONFO 05-20-2025
- APTO 05-13-2025
- Dividend Yield
- ONFO N/A
- APTO N/A
- EPS Growth
- ONFO N/A
- APTO N/A
- EPS
- ONFO N/A
- APTO N/A
- Revenue
- ONFO $6,590,171.00
- APTO N/A
- Revenue This Year
- ONFO $133.59
- APTO N/A
- Revenue Next Year
- ONFO N/A
- APTO N/A
- P/E Ratio
- ONFO N/A
- APTO N/A
- Revenue Growth
- ONFO 29.25
- APTO N/A
- 52 Week Low
- ONFO $0.39
- APTO $1.35
- 52 Week High
- ONFO $1.88
- APTO $50.10
- Technical
- Relative Strength Index (RSI)
- ONFO 40.53
- APTO 26.12
- Support Level
- ONFO $0.61
- APTO $3.20
- Resistance Level
- ONFO $1.38
- APTO $3.43
- Average True Range (ATR)
- ONFO 0.11
- APTO 0.35
- MACD
- ONFO -0.03
- APTO -0.06
- Stochastic Oscillator
- ONFO 41.34
- APTO 13.69
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place.
About APTO Aptose Biosciences Inc.
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.